DK1641461T3 - Kombinationsprodukt omfattende en histamin H3 receptor antagonist eller invers agonist og et antipsykotisk eller antidepressivt middel, og anvendelse deraf i fremstillingen af et medikament som forebygger de negative virkninger af psykotropiske ... - Google Patents
Kombinationsprodukt omfattende en histamin H3 receptor antagonist eller invers agonist og et antipsykotisk eller antidepressivt middel, og anvendelse deraf i fremstillingen af et medikament som forebygger de negative virkninger af psykotropiske ...Info
- Publication number
- DK1641461T3 DK1641461T3 DK04767475.9T DK04767475T DK1641461T3 DK 1641461 T3 DK1641461 T3 DK 1641461T3 DK 04767475 T DK04767475 T DK 04767475T DK 1641461 T3 DK1641461 T3 DK 1641461T3
- Authority
- DK
- Denmark
- Prior art keywords
- inverse agonist
- antidepressant
- histamine
- antipsychotic
- psychotropic
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 7
- 230000001430 anti-depressive effect Effects 0.000 title abstract 3
- 230000000561 anti-psychotic effect Effects 0.000 title abstract 3
- 239000000935 antidepressant agent Substances 0.000 title abstract 3
- 229940005513 antidepressants Drugs 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 title 1
- 229940122931 Histamine H3 receptor inverse agonist Drugs 0.000 title 1
- 230000002411 adverse Effects 0.000 title 1
- 239000013066 combination product Substances 0.000 title 1
- 229940127555 combination product Drugs 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 230000000506 psychotropic effect Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 abstract 3
- 229940125425 inverse agonist Drugs 0.000 abstract 3
- 102000004384 Histamine H3 receptors Human genes 0.000 abstract 2
- 108090000981 Histamine H3 receptors Proteins 0.000 abstract 2
- 230000001629 suppression Effects 0.000 abstract 2
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010039897 Sedation Diseases 0.000 abstract 1
- 230000036626 alertness Effects 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 230000036461 convulsion Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000036280 sedation Effects 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0307836A FR2856596B1 (fr) | 2003-06-27 | 2003-06-27 | Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes. |
PCT/FR2004/001628 WO2005000315A1 (fr) | 2003-06-27 | 2004-06-25 | Association d'un antagoniste ou agoniste inverse du recepteur h3 de l'histamine avec un anti-psychotique ou un antidepresseur et son utilisation pour preparer un medicament prevenant des effets indesirables de medicaments psychotropes |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1641461T3 true DK1641461T3 (da) | 2011-01-10 |
Family
ID=33515484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04767475.9T DK1641461T3 (da) | 2003-06-27 | 2004-06-25 | Kombinationsprodukt omfattende en histamin H3 receptor antagonist eller invers agonist og et antipsykotisk eller antidepressivt middel, og anvendelse deraf i fremstillingen af et medikament som forebygger de negative virkninger af psykotropiske ... |
Country Status (16)
Country | Link |
---|---|
US (1) | US8106041B2 (da) |
EP (1) | EP1641461B1 (da) |
JP (1) | JP4800936B2 (da) |
KR (1) | KR20060094847A (da) |
AT (1) | ATE482711T1 (da) |
CA (1) | CA2530381C (da) |
CY (1) | CY1110947T1 (da) |
DE (1) | DE602004029364D1 (da) |
DK (1) | DK1641461T3 (da) |
ES (1) | ES2350103T3 (da) |
FR (1) | FR2856596B1 (da) |
MX (1) | MXPA05013877A (da) |
PL (1) | PL1641461T3 (da) |
PT (1) | PT1641461E (da) |
SI (1) | SI1641461T1 (da) |
WO (1) | WO2005000315A1 (da) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR048134A1 (es) * | 2003-12-15 | 2006-04-05 | Lundbeck & Co As H | La combinacion de un inhibidor de la recaptacion de serotonina y un antagonista del receptor de la histamina 3, el agonista inverso o el agonista parcial |
US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
US7487265B2 (en) * | 2004-04-16 | 2009-02-03 | Sandisk Corporation | Memory card with two standard sets of contacts and a hinged contact covering mechanism |
EP1707203A1 (en) * | 2005-04-01 | 2006-10-04 | Bioprojet | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands |
EP1717233A1 (en) * | 2005-04-29 | 2006-11-02 | Bioprojet | Histamine H3-receptor ligands and their therapeutic application |
US7831915B2 (en) | 2005-11-10 | 2010-11-09 | Microsoft Corporation | Dynamically protecting against web resources associated with undesirable activities |
JP5227182B2 (ja) | 2005-12-19 | 2013-07-03 | アボット・ラボラトリーズ | 1型および2型サイトカイン産生における不均衡を調節するためのベータ−ヒドロキシ−ベータ−メチルブチラートの使用 |
AU2007260836B2 (en) | 2006-06-23 | 2012-11-15 | Abbvie Bahamas Ltd. | Cyclopropyl amine derivatives as histamin H3 receptor modulators |
US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
FR2903904A1 (fr) * | 2006-07-21 | 2008-01-25 | Bioprojet Soc Civ Ile | Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3 |
EP2167096A4 (en) * | 2007-06-13 | 2010-07-14 | Cypress Bioscience Inc | IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM |
US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
RU2012125881A (ru) | 2010-01-29 | 2014-03-10 | Эбботт Лэборетриз | Питательные эмульсии, содержащие бета-гидрокси-бета-метилбутират кальция (гмб кальция) |
CN102711522B (zh) | 2010-01-29 | 2015-09-09 | 雅培制药有限公司 | 包含hmb的无菌包装的营养液 |
US9693577B2 (en) | 2010-01-29 | 2017-07-04 | Abbott Laboratories | Method of preparing a nutritional powder comprising spray dried HMB |
TWI526161B (zh) | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣hmb及可溶性蛋白質之實質上透明營養液 |
WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
JO3637B1 (ar) | 2015-04-28 | 2020-08-27 | Janssen Sciences Ireland Uc | مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv |
TW201932470A (zh) | 2017-11-29 | 2019-08-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 具有抗rsv活性之吡唑并嘧啶 |
US11491157B2 (en) | 2018-01-31 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company Co Cork, IE | Cycloalkyl substituted pyrazolopyrimidines having activity against RSV |
CA3095277A1 (en) | 2018-04-23 | 2019-10-31 | Janssen Sciences Ireland Unlimited Company | Heteroaromatic compounds having activity against rsv |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2732017B1 (fr) * | 1995-03-21 | 2000-09-22 | Inst Nat Sante Rech Med | Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques |
EP0982300A3 (en) | 1998-07-29 | 2000-03-08 | Societe Civile Bioprojet | Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications |
US20030096808A1 (en) * | 1999-03-29 | 2003-05-22 | Jon M. Miller | Substance to prevent or reverse weight gain induced by psychoactive agents |
AU4973800A (en) * | 1999-06-09 | 2000-12-28 | Eli Lilly And Company | Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist |
MXPA03001267A (es) * | 2000-08-08 | 2004-07-30 | Johnson & Johnson | Ariloxialquilaminas sin imidazol. |
-
2003
- 2003-06-27 FR FR0307836A patent/FR2856596B1/fr not_active Expired - Fee Related
-
2004
- 2004-06-25 PT PT04767475T patent/PT1641461E/pt unknown
- 2004-06-25 MX MXPA05013877A patent/MXPA05013877A/es active IP Right Grant
- 2004-06-25 CA CA2530381A patent/CA2530381C/fr active Active
- 2004-06-25 JP JP2006516331A patent/JP4800936B2/ja not_active Expired - Fee Related
- 2004-06-25 SI SI200431513T patent/SI1641461T1/sl unknown
- 2004-06-25 US US10/562,396 patent/US8106041B2/en active Active
- 2004-06-25 AT AT04767475T patent/ATE482711T1/de active
- 2004-06-25 ES ES04767475T patent/ES2350103T3/es active Active
- 2004-06-25 DK DK04767475.9T patent/DK1641461T3/da active
- 2004-06-25 EP EP04767475A patent/EP1641461B1/fr active Active
- 2004-06-25 PL PL04767475T patent/PL1641461T3/pl unknown
- 2004-06-25 DE DE602004029364T patent/DE602004029364D1/de active Active
- 2004-06-25 WO PCT/FR2004/001628 patent/WO2005000315A1/fr active Application Filing
- 2004-06-25 KR KR1020057024963A patent/KR20060094847A/ko active Search and Examination
-
2010
- 2010-11-24 CY CY20101101070T patent/CY1110947T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP4800936B2 (ja) | 2011-10-26 |
PT1641461E (pt) | 2010-10-13 |
CA2530381A1 (fr) | 2005-01-06 |
CA2530381C (fr) | 2013-03-12 |
US20060210624A1 (en) | 2006-09-21 |
CY1110947T1 (el) | 2015-06-10 |
MXPA05013877A (es) | 2006-03-13 |
FR2856596A1 (fr) | 2004-12-31 |
JP2007516160A (ja) | 2007-06-21 |
PL1641461T3 (pl) | 2011-02-28 |
KR20060094847A (ko) | 2006-08-30 |
EP1641461A1 (fr) | 2006-04-05 |
DE602004029364D1 (de) | 2010-11-11 |
FR2856596B1 (fr) | 2007-04-27 |
EP1641461B1 (fr) | 2010-09-29 |
ATE482711T1 (de) | 2010-10-15 |
SI1641461T1 (sl) | 2010-12-31 |
US8106041B2 (en) | 2012-01-31 |
ES2350103T3 (es) | 2011-01-18 |
WO2005000315A1 (fr) | 2005-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1641461T3 (da) | Kombinationsprodukt omfattende en histamin H3 receptor antagonist eller invers agonist og et antipsykotisk eller antidepressivt middel, og anvendelse deraf i fremstillingen af et medikament som forebygger de negative virkninger af psykotropiske ... | |
ATE454372T1 (de) | Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen | |
ATE478856T1 (de) | Spirobenzodioxole und deren verwendung als cb1- antagonisten | |
SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
TW200716522A (en) | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | |
UA102517C2 (ru) | Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы | |
CR7432A (es) | Amidas sustituidas activas del receptor de canabinoide-1 | |
MY155255A (en) | Spiro-oxindole compounds and their use as therapeutic agents | |
ATE445609T1 (de) | Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen | |
ATE384058T1 (de) | Thiazolderivate | |
MX2007008614A (es) | Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r). | |
MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
NO20081844L (no) | Terapeutiske forbindelser | |
UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
MXPA05013733A (es) | 2-aminobenzotiazoles como agonistas inversos del receptor de cb1. | |
ATE412636T1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
EA200970405A1 (ru) | Соединения, проявляющие активность в отношении рецептора св | |
PH12021550549A1 (en) | Dp antagonist | |
WO2009096701A3 (en) | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | |
MX2008002456A (es) | Uso de ambroxol para el tratamiento de infecciones por rinovirus. | |
NO20092764L (no) | Isosorbid mononitrat derivater for behandling av okular hypertensjon | |
MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
UA83868C2 (ru) | Производные бензимидазолона и хиназолинона в качестве агонистов человеческих рецепторов orl1 | |
MX2020008523A (es) | Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5). | |
MX2019015606A (es) | Nuevos usos de un antagonista del receptor 5-ht6 puro. |